8-K
filed July 11, 2023, 7:59 PM ET
CIK 0001410939
M&A
confidence high
sentiment neutral
materiality 1.00
IVERIC bio, Inc.: M&A transaction — Astellas completes $5.9B acquisition of IVERIC bio; shareholders receive $40.00 per share
IVERIC bio, Inc.
- Merger completed July 11, 2023; each IVERIC share converted to $40.00 cash.
- Aggregate purchase price ~$5.9B, funded by Astellas via cash and credit.
- Board of directors resigned at effective time; replaced by sole director/officer from Merger Sub.
- IVERIC to delist from Nasdaq and deregister shares with SEC.
- Credit agreement with Hercules Capital repaid in full and terminated.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 1.0
Mark S. Blumenkranz resigned as Director at IVERIC bio, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of the directors of IVERIC (Glenn P. Sblendorio, Pravin U. Dugel, Mark S. Blumenkranz, Axel Bolte, Adrienne L. Graves, Jane P. Henderson, Christine A. Miller and Calvin W. Roberts) resigned as a member of the board of directors of IVERIC as of the Effective Time.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Calvin W. Roberts resigned as Director at IVERIC bio, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of the directors of IVERIC (Glenn P. Sblendorio, Pravin U. Dugel, Mark S. Blumenkranz, Axel Bolte, Adrienne L. Graves, Jane P. Henderson, Christine A. Miller and Calvin W. Roberts) resigned as a member of the board of directors of IVERIC as of the Effective Time.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Axel Bolte resigned as Director at IVERIC bio, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of the directors of IVERIC (Glenn P. Sblendorio, Pravin U. Dugel, Mark S. Blumenkranz, Axel Bolte, Adrienne L. Graves, Jane P. Henderson, Christine A. Miller and Calvin W. Roberts) resigned as a member of the board of directors of IVERIC as of the Effective Time.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Jane P. Henderson resigned as Director at IVERIC bio, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of the directors of IVERIC (Glenn P. Sblendorio, Pravin U. Dugel, Mark S. Blumenkranz, Axel Bolte, Adrienne L. Graves, Jane P. Henderson, Christine A. Miller and Calvin W. Roberts) resigned as a member of the board of directors of IVERIC as of the Effective Time.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Pravin U. Dugel resigned as Director at IVERIC bio, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of the directors of IVERIC (Glenn P. Sblendorio, Pravin U. Dugel, Mark S. Blumenkranz, Axel Bolte, Adrienne L. Graves, Jane P. Henderson, Christine A. Miller and Calvin W. Roberts) resigned as a member of the board of directors of IVERIC as of the Effective Time.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Mark Reisenauer was appointed as Director at IVERIC bio, Inc..
- Action
- became
- Role
- Director
Exact text from the filing
at the Effective Time, the sole director of Merger Sub became the sole director of IVERIC.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Christine A. Miller resigned as Director at IVERIC bio, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of the directors of IVERIC (Glenn P. Sblendorio, Pravin U. Dugel, Mark S. Blumenkranz, Axel Bolte, Adrienne L. Graves, Jane P. Henderson, Christine A. Miller and Calvin W. Roberts) resigned as a member of the board of directors of IVERIC as of the Effective Time.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Glenn P. Sblendorio resigned as Director at IVERIC bio, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of the directors of IVERIC (Glenn P. Sblendorio, Pravin U. Dugel, Mark S. Blumenkranz, Axel Bolte, Adrienne L. Graves, Jane P. Henderson, Christine A. Miller and Calvin W. Roberts) resigned as a member of the board of directors of IVERIC as of the Effective Time.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Mark Reisenauer was appointed as Officer at IVERIC bio, Inc..
- Action
- became
- Role
- Officer
Exact text from the filing
at the Effective Time, the sole officer of Merger Sub became the sole officer of IVERIC.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Adrienne L. Graves resigned as Director at IVERIC bio, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of the directors of IVERIC (Glenn P. Sblendorio, Pravin U. Dugel, Mark S. Blumenkranz, Axel Bolte, Adrienne L. Graves, Jane P. Henderson, Christine A. Miller and Calvin W. Roberts) resigned as a member of the board of directors of IVERIC as of the Effective Time.
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
IVERIC bio, Inc.: Amended and restated the certificate of incorporation to conform to the form set forth in the merger agreement.
- Change
- charter amendment
Exact text from the filing
At the Effective Time, the Restated Certificate of Incorporation of IVERIC, as in effect immediately prior to the Effective Time, was amended and restated to be in the form of the amended and restated certificate of incorporation set forth on Annex I to the Merger Agreement
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
IVERIC bio, Inc.: Amended and restated the bylaws to conform to the bylaws of Merger Sub.
- Change
- bylaw amendment
Exact text from the filing
In addition, at the Effective Time, IVERIC’s bylaws, as in effect immediately prior to the Effective Time, were amended and restated to conform to the bylaws of Merger Sub as of immediately prior to the Effective Time, except that references to the name of Merger Sub were replaced by the name of IVERIC
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
IVERIC bio, Inc. underwent a change of control involving Astellas US Holding, Inc. for $40.00 per Share in cash (closed 2023-07-11).
- Action
- change of control
- Counterparty
- Astellas US Holding, Inc.
- Consideration
- $40.00 per Share in cash
- Closing
- 2023-07-11
Exact text from the filing
of common stock, par value $0.001 per share, of IVERIC (a “ Share ”) outstanding immediately prior to the effective time of the Merger was converted into the right to receive $40.00 per Share in cash, without interest (the “ Per Share Merger Consideration ”) less any applicable withholding taxes (except for any Shares owned by (1) IVERIC, (2) Parent or Merger
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
IVERIC bio, Inc. terminated IVERIC Credit Agreement with Hercules Capital, Inc., as administrative agent and collateral agent (effective 2023-07-11).
- Action
- termination
- Agreement
- credit facility
- Counterparty
- Hercules Capital, Inc., as administrative agent and collateral agent
- Effective
- 2023-07-11
Exact text from the filing
On July 11, 2023, in connection with the Merger, IVERIC repaid in full all outstanding indebtedness and all other amounts due and payable and terminated all commitments under that certain Loan and Security Agreement, dated as of July 26, 2022 (as amended, restated, amended and restated, supplemented and otherwise modified from time to time prior to the Closing Date, the “ IVERIC Credit Agreement ”), by and among IVERIC and each of its subsidiaries party thereto, as borrowers, the lenders party thereto and Hercules Capital, Inc., as administrative agent and collateral agent.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.